ALDER BIOPHARMACEUTICALS INC - FORM S-1/A - EX-10.25 - 1ST AMENDMENT TO MASTER PRODUCT DEVELOPMENT & CLINICAL SUPPLY AGREEMENT - April 25, 2014

Attached files

file filename
S-1/A - S-1/A - ALDER BIOPHARMACEUTICALS INCd657876ds1a.htm
EX-1.1 - FORM OF UNDERWRITING AGREEMENT - ALDER BIOPHARMACEUTICALS INCd657876dex11.htm
EX-10.24 - MASTER PRODUCT DEVELOPMENT & CLINICAL SUPPLY AGREEMENT - ALDER BIOPHARMACEUTICALS INCd657876dex1024.htm
EX-5.1 - OPINION OF COOLEY LLP - ALDER BIOPHARMACEUTICALS INCd657876dex51.htm
EX-4.2 - AMENDMENT NO. 1 TO AMENDED AND RESTATED INVESTORS' RIGHST AGREEMENT - ALDER BIOPHARMACEUTICALS INCd657876dex42.htm
EX-3.3 - FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - ALDER BIOPHARMACEUTICALS INCd657876dex33.htm
EX-10.5 - FORM OF STOCK OPTION GRANT NOTICE AND OPTION AGREEMENT - ALDER BIOPHARMACEUTICALS INCd657876dex105.htm
EX-10.4 - 2014 EQUITY INCENTIVE PLAN - ALDER BIOPHARMACEUTICALS INCd657876dex104.htm
EX-3.5 - FORM OF AMENDED AND RESTATED BYLAWS - ALDER BIOPHARMACEUTICALS INCd657876dex35.htm
EX-10.1 - FORM OF INDEMNITY AGREEMENT BETWEEN THE ALDER BIOPHARMACEUTICALS, INC - ALDER BIOPHARMACEUTICALS INCd657876dex101.htm
EX-23.1 - CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - ALDER BIOPHARMACEUTICALS INCd657876dex231.htm
EX-3.2 - CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION - ALDER BIOPHARMACEUTICALS INCd657876dex32.htm
EX-10.7 - FORM OF EXECUTIVE SEVERANCE BENEFIT PLAN - ALDER BIOPHARMACEUTICALS INCd657876dex107.htm

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

EXHIBIT 10.25

FIRST AMENDMENT TO

MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT

THIS FIRST AMENDMENT TO MASTER PRODUCT DEVELOPMENT AND CLINICAL SUPPLY AGREEMENT (“Amendment”) is entered into effective as of March 15, 2013 (the “Effective Date”) between Alder Biopharmaceuticals, Inc., a Delaware corporation, with its principal offices at 11804 North Creek Parkway South, Bothell, WA 98011 (“Client”) and Althea Technologies, Inc., a Delaware corporation, with its principal offices at 11040 Roselle Street, San Diego, CA 92121 (“Althea”), in order to amend that certain Master Product Development and Clinical Supply Agreement between Client and Althea dated March 21, 2011 (the “Agreement”). The parties agree as follows:

1. The first sentence in Section 3.1 (Term) in the Agreement is hereby amended to read in its entirety as follows: “This Agreement shall commence on the Effective Date and will continue until the later of (a) [***], and (b) the date on which the Production services, as described in the last outstanding PWA, have been completed, unless sooner terminated pursuant to Section 3.2 herein (the “Term”).

2. All other terms and conditions of the Agreement remain unchanged and in full force and effect. In the event of a conflict between the Agreement and this Amendment, this Amendment will control.

3. This Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which shall constitute one and the same instrument. This Amendment shall be effective upon full execution, and a facsimile or other electronic signature shall be deemed to be and shall be as effective as an original signature.

IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their duly authorized representatives as of the Effective Date.

 

ALDER BIOPHARMACEUTICALS, INC.     ALTHEA TECHNOLOGIES, INC.
By:  

/s/ Mark J. Litton, Ph.D.

     By:  

/s/ Martha J. Demski

Name:   Mark J. Litton, Ph.D.     Name:   Martha J. Demski
Title:   Chief Business Officer     Title:   SVP and CFO
Date:  

March 15, 2013

     Date:  

2013.03.19         10:25:10-07’00’

Althea & Alder Confidential

ALDER BIOPHARMACEUTICALS INC Reports